Keith R. Gollust is Director at SYNTA PHARMACEUTICALS CORP (SNTA). They have made 13 open-market trades across 1 company since 2007, most recently 2015-12-14.
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
9 open-market purchases totalling $6.2M since 2007, against 4 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| SNTA | 1,839,169 | — |
Shares reported on the most recent Form 4, priced at the 2015-12-15 close. 1 holding could not be priced and is excluded from the total.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| SNTA | SELL | 2015-12-11 | 2015-12-15 | $0.35 | $207K | N/A | N/A | N/A |
| SNTA | SELL | 2015-12-07 | 2015-12-09 | $0.38 | $286K | N/A | N/A | N/A |
| SNTA | SELL | 2015-11-17 | 2015-11-19 | $0.41 | $41K | N/A | N/A | N/A |
| SNTA | SELL | 2015-11-10 | 2015-11-13 | $0.55 | $104K | N/A | N/A | N/A |
| SNTA | BUY | 2015-04-06 | 2015-04-08 | $1.75 | $613K | N/A | N/A | N/A |
| SNTA | BUY | 2013-11-13 | 2013-11-15 | $3.75 | $563K | N/A | N/A | N/A |
| SNTA | BUY | 2012-06-29 | 2012-07-02 | $5.35 | $803K | N/A | N/A | N/A |
| SNTA | BUY | 2011-04-14 | 2011-04-18 | $4.89 | $489K | N/A | N/A | N/A |
| SNTA | BUY | 2010-01-08 | 2010-01-12 | $4.50 | $450K | N/A | N/A | N/A |
| SNTA | BUY | 2008-08-11 | 2008-08-13 | $7.51 | $878K | N/A | N/A | N/A |
| SNTA | BUY | 2008-05-29 | 2008-06-02 | $7.16 | $215K | N/A | N/A | N/A |
| SNTA | BUY | 2008-05-16 | 2008-05-20 | $7.05 | $352K | N/A | N/A | N/A |
| SNTA | BUY | 2007-02-09 | 2007-02-13 | $10.00 | $1.8M | N/A | N/A | N/A |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.